Quest Diagnostics — Jul 22, 2025 release

of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 • Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 • Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83 SECAUCUS, N.J., July 22, 2025 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025. "Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15.2% which includes 5.2% from organic revenues, as well as adjusted EPS growth of 11.5%," said Jim Davis, Chairman, CEO and President. "Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance." Three Months Ended June 30, Six Months Ended June 30, 2025 2024 Change 2025 2024 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,761  $ 2,397  15.2  % $ 5,413  $ 4,763  13.7  % Diagnostic Information Services revenues $ 2,699  $ 2,333  15.7  % $ 5,288  $ 4,631  14.2  % Revenue pe